Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose Escalation, Safety and Pharmacokinetic Phase 1 Study With AVE8062 Administered as a 30 Minutes Intravenous Infusion Followed by Docetaxel Administered as an 1 Hour Intravenous Infusion 24 Hours-Apart Every 3 Weeks in Patients With Advanced Solid Tumors

NCT01907685 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01907685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01907685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose Escalation, Safety and Pharmacokinetic Phase 1 Study With AVE8062 Administered as a 30 Minutes Intravenous Infusion Followed by Docetaxel Administered as an 1 Hour Intravenous Infusion 24 Hours-Apart Every 3 Weeks in Patients With Advanced Solid Tumors
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2006
Completion date
February 28, 2011
Enrollment
58 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced neoplastic disease